Pembrolizumab shows real promise against head and neck cancer, study suggests

29 mayo 2015

Immunotherapy with the anti-PD-1 antibody pembrolizumab decreased the size of tumors by 30 percent or more in 24.8 percent of 132 patients with recurrent or metastatic head and neck cancer. That’s nearly twice as effective as the current preferred treatment.